nodes	percent_of_prediction	percent_of_DWPC	metapath
Everolimus—CYP3A4—Temozolomide—brain cancer	0.146	0.486	CbGbCtD
Everolimus—CYP3A4—Lomustine—brain cancer	0.124	0.414	CbGbCtD
Everolimus—CYP3A4—Etoposide—brain cancer	0.0301	0.1	CbGbCtD
Everolimus—MTOR—blood vessel—brain cancer	0.00835	0.111	CbGeAlD
Everolimus—MTOR—hindbrain—brain cancer	0.00797	0.106	CbGeAlD
Everolimus—MTOR—brainstem—brain cancer	0.00457	0.0606	CbGeAlD
Everolimus—MTOR—telencephalon—brain cancer	0.00405	0.0538	CbGeAlD
Everolimus—FKBP1A—telencephalon—brain cancer	0.00364	0.0484	CbGeAlD
Everolimus—MTOR—gonad—brain cancer	0.00338	0.0449	CbGeAlD
Everolimus—MTOR—pituitary gland—brain cancer	0.0033	0.0438	CbGeAlD
Everolimus—FKBP1A—gonad—brain cancer	0.00304	0.0404	CbGeAlD
Everolimus—FKBP1A—pituitary gland—brain cancer	0.00297	0.0394	CbGeAlD
Everolimus—FKBP1A—medulla oblongata—brain cancer	0.00286	0.038	CbGeAlD
Everolimus—MTOR—spinal cord—brain cancer	0.00284	0.0377	CbGeAlD
Everolimus—FKBP1A—midbrain—brain cancer	0.00262	0.0347	CbGeAlD
Everolimus—MTOR—endocrine gland—brain cancer	0.00256	0.0339	CbGeAlD
Everolimus—FKBP1A—spinal cord—brain cancer	0.00255	0.0339	CbGeAlD
Everolimus—MTOR—head—brain cancer	0.00252	0.0335	CbGeAlD
Everolimus—MTOR—central nervous system—brain cancer	0.0023	0.0306	CbGeAlD
Everolimus—FKBP1A—endocrine gland—brain cancer	0.0023	0.0305	CbGeAlD
Everolimus—FKBP1A—head—brain cancer	0.00227	0.0301	CbGeAlD
Everolimus—MTOR—cerebellum—brain cancer	0.00225	0.0299	CbGeAlD
Everolimus—FKBP1A—central nervous system—brain cancer	0.00207	0.0275	CbGeAlD
Everolimus—FKBP1A—cerebellum—brain cancer	0.00202	0.0269	CbGeAlD
Everolimus—MTOR—brain—brain cancer	0.00183	0.0243	CbGeAlD
Everolimus—FKBP1A—brain—brain cancer	0.00164	0.0218	CbGeAlD
Everolimus—CYP3A4—endocrine gland—brain cancer	0.000751	0.00997	CbGeAlD
Everolimus—CYP3A4—central nervous system—brain cancer	0.000677	0.00898	CbGeAlD
Everolimus—Stomatitis—Temozolomide—brain cancer	0.000539	0.00132	CcSEcCtD
Everolimus—Urinary tract infection—Temozolomide—brain cancer	0.000538	0.00132	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Procarbazine—brain cancer	0.000532	0.0013	CcSEcCtD
Everolimus—Insomnia—Procarbazine—brain cancer	0.000528	0.00129	CcSEcCtD
Everolimus—Paraesthesia—Procarbazine—brain cancer	0.000524	0.00128	CcSEcCtD
Everolimus—Hepatobiliary disease—Temozolomide—brain cancer	0.000523	0.00128	CcSEcCtD
Everolimus—Sinusitis—Temozolomide—brain cancer	0.000519	0.00127	CcSEcCtD
Everolimus—Somnolence—Procarbazine—brain cancer	0.000519	0.00127	CcSEcCtD
Everolimus—Haemoglobin—Carmustine—brain cancer	0.000517	0.00126	CcSEcCtD
Everolimus—Haemorrhage—Carmustine—brain cancer	0.000514	0.00126	CcSEcCtD
Everolimus—Ill-defined disorder—Hydroxyurea—brain cancer	0.000513	0.00126	CcSEcCtD
Everolimus—Anaemia—Hydroxyurea—brain cancer	0.000512	0.00125	CcSEcCtD
Everolimus—Hallucination—Carmustine—brain cancer	0.000511	0.00125	CcSEcCtD
Everolimus—Hypoaesthesia—Carmustine—brain cancer	0.000511	0.00125	CcSEcCtD
Everolimus—Decreased appetite—Procarbazine—brain cancer	0.000507	0.00124	CcSEcCtD
Everolimus—Alanine aminotransferase increased—Etoposide—brain cancer	0.000507	0.00124	CcSEcCtD
Everolimus—Oedema peripheral—Carmustine—brain cancer	0.000506	0.00124	CcSEcCtD
Everolimus—Connective tissue disorder—Carmustine—brain cancer	0.000505	0.00124	CcSEcCtD
Everolimus—Fatigue—Procarbazine—brain cancer	0.000503	0.00123	CcSEcCtD
Everolimus—Haemoglobin—Temozolomide—brain cancer	0.000499	0.00122	CcSEcCtD
Everolimus—Malaise—Hydroxyurea—brain cancer	0.000499	0.00122	CcSEcCtD
Everolimus—Pain—Procarbazine—brain cancer	0.000499	0.00122	CcSEcCtD
Everolimus—Constipation—Procarbazine—brain cancer	0.000499	0.00122	CcSEcCtD
Everolimus—Haemorrhage—Temozolomide—brain cancer	0.000497	0.00122	CcSEcCtD
Everolimus—Hepatitis—Temozolomide—brain cancer	0.000497	0.00122	CcSEcCtD
Everolimus—Dysphagia—Etoposide—brain cancer	0.000497	0.00122	CcSEcCtD
Everolimus—Leukopenia—Hydroxyurea—brain cancer	0.000495	0.00121	CcSEcCtD
Everolimus—Hypoaesthesia—Temozolomide—brain cancer	0.000494	0.00121	CcSEcCtD
Everolimus—Hallucination—Temozolomide—brain cancer	0.000494	0.00121	CcSEcCtD
Everolimus—Pharyngitis—Temozolomide—brain cancer	0.000493	0.00121	CcSEcCtD
Everolimus—Urinary tract disorder—Temozolomide—brain cancer	0.00049	0.0012	CcSEcCtD
Everolimus—Oedema peripheral—Temozolomide—brain cancer	0.000489	0.0012	CcSEcCtD
Everolimus—Bronchospasm—Etoposide—brain cancer	0.000488	0.0012	CcSEcCtD
Everolimus—Connective tissue disorder—Temozolomide—brain cancer	0.000488	0.00119	CcSEcCtD
Everolimus—Urethral disorder—Temozolomide—brain cancer	0.000487	0.00119	CcSEcCtD
Everolimus—Feeling abnormal—Procarbazine—brain cancer	0.000481	0.00118	CcSEcCtD
Everolimus—Eye disorder—Carmustine—brain cancer	0.00048	0.00118	CcSEcCtD
Everolimus—Convulsion—Hydroxyurea—brain cancer	0.00048	0.00117	CcSEcCtD
Everolimus—Gastrointestinal pain—Procarbazine—brain cancer	0.000477	0.00117	CcSEcCtD
Everolimus—Flushing—Carmustine—brain cancer	0.000477	0.00117	CcSEcCtD
Everolimus—Pancytopenia—Etoposide—brain cancer	0.000472	0.00115	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—brain cancer	0.000468	0.00115	CcSEcCtD
Everolimus—Discomfort—Hydroxyurea—brain cancer	0.000466	0.00114	CcSEcCtD
Everolimus—Neutropenia—Etoposide—brain cancer	0.000464	0.00114	CcSEcCtD
Everolimus—Eye disorder—Temozolomide—brain cancer	0.000464	0.00114	CcSEcCtD
Everolimus—Abdominal pain—Procarbazine—brain cancer	0.000461	0.00113	CcSEcCtD
Everolimus—Body temperature increased—Procarbazine—brain cancer	0.000461	0.00113	CcSEcCtD
Everolimus—Flushing—Temozolomide—brain cancer	0.000461	0.00113	CcSEcCtD
Everolimus—Cardiac disorder—Temozolomide—brain cancer	0.000461	0.00113	CcSEcCtD
Everolimus—Alopecia—Carmustine—brain cancer	0.000454	0.00111	CcSEcCtD
Everolimus—Oedema—Hydroxyurea—brain cancer	0.000452	0.00111	CcSEcCtD
Everolimus—Angiopathy—Temozolomide—brain cancer	0.000451	0.0011	CcSEcCtD
Everolimus—Mental disorder—Carmustine—brain cancer	0.00045	0.0011	CcSEcCtD
Everolimus—Infection—Hydroxyurea—brain cancer	0.000449	0.0011	CcSEcCtD
Everolimus—Immune system disorder—Temozolomide—brain cancer	0.000449	0.0011	CcSEcCtD
Everolimus—Mediastinal disorder—Temozolomide—brain cancer	0.000448	0.0011	CcSEcCtD
Everolimus—Erythema—Carmustine—brain cancer	0.000447	0.00109	CcSEcCtD
Everolimus—Malnutrition—Carmustine—brain cancer	0.000447	0.00109	CcSEcCtD
Everolimus—Chills—Temozolomide—brain cancer	0.000446	0.00109	CcSEcCtD
Everolimus—Pneumonia—Etoposide—brain cancer	0.000445	0.00109	CcSEcCtD
Everolimus—Nervous system disorder—Hydroxyurea—brain cancer	0.000443	0.00108	CcSEcCtD
Everolimus—Infestation—Etoposide—brain cancer	0.000443	0.00108	CcSEcCtD
Everolimus—Infestation NOS—Etoposide—brain cancer	0.000443	0.00108	CcSEcCtD
Everolimus—Thrombocytopenia—Hydroxyurea—brain cancer	0.000442	0.00108	CcSEcCtD
Everolimus—Alopecia—Temozolomide—brain cancer	0.000439	0.00107	CcSEcCtD
Everolimus—Skin disorder—Hydroxyurea—brain cancer	0.000439	0.00107	CcSEcCtD
Everolimus—Acute coronary syndrome—Etoposide—brain cancer	0.000436	0.00107	CcSEcCtD
Everolimus—Renal failure—Etoposide—brain cancer	0.000435	0.00107	CcSEcCtD
Everolimus—Mental disorder—Temozolomide—brain cancer	0.000435	0.00106	CcSEcCtD
Everolimus—Myocardial infarction—Etoposide—brain cancer	0.000434	0.00106	CcSEcCtD
Everolimus—Back pain—Carmustine—brain cancer	0.000433	0.00106	CcSEcCtD
Everolimus—Malnutrition—Temozolomide—brain cancer	0.000432	0.00106	CcSEcCtD
Everolimus—Erythema—Temozolomide—brain cancer	0.000432	0.00106	CcSEcCtD
Everolimus—Jaundice—Etoposide—brain cancer	0.000432	0.00106	CcSEcCtD
Everolimus—Stomatitis—Etoposide—brain cancer	0.000432	0.00106	CcSEcCtD
Everolimus—Anorexia—Hydroxyurea—brain cancer	0.000431	0.00105	CcSEcCtD
Everolimus—Hypersensitivity—Procarbazine—brain cancer	0.00043	0.00105	CcSEcCtD
Everolimus—Dysgeusia—Temozolomide—brain cancer	0.000423	0.00104	CcSEcCtD
Everolimus—Vision blurred—Carmustine—brain cancer	0.000422	0.00103	CcSEcCtD
Everolimus—Tremor—Carmustine—brain cancer	0.000419	0.00103	CcSEcCtD
Everolimus—Asthenia—Procarbazine—brain cancer	0.000419	0.00102	CcSEcCtD
Everolimus—Hepatobiliary disease—Etoposide—brain cancer	0.000419	0.00102	CcSEcCtD
Everolimus—Back pain—Temozolomide—brain cancer	0.000418	0.00102	CcSEcCtD
Everolimus—Anaemia—Carmustine—brain cancer	0.000414	0.00101	CcSEcCtD
Everolimus—Pruritus—Procarbazine—brain cancer	0.000413	0.00101	CcSEcCtD
Everolimus—Agitation—Carmustine—brain cancer	0.000411	0.00101	CcSEcCtD
Everolimus—Vision blurred—Temozolomide—brain cancer	0.000407	0.000997	CcSEcCtD
Everolimus—Tremor—Temozolomide—brain cancer	0.000405	0.000991	CcSEcCtD
Everolimus—Dyspnoea—Hydroxyurea—brain cancer	0.000403	0.000986	CcSEcCtD
Everolimus—Somnolence—Hydroxyurea—brain cancer	0.000402	0.000983	CcSEcCtD
Everolimus—Ill-defined disorder—Temozolomide—brain cancer	0.000401	0.000982	CcSEcCtD
Everolimus—Leukopenia—Carmustine—brain cancer	0.0004	0.00098	CcSEcCtD
Everolimus—Anaemia—Temozolomide—brain cancer	0.0004	0.000978	CcSEcCtD
Everolimus—Diarrhoea—Procarbazine—brain cancer	0.000399	0.000977	CcSEcCtD
Everolimus—Dyspepsia—Hydroxyurea—brain cancer	0.000398	0.000973	CcSEcCtD
Everolimus—Agitation—Temozolomide—brain cancer	0.000397	0.000972	CcSEcCtD
Everolimus—Hypoaesthesia—Etoposide—brain cancer	0.000395	0.000968	CcSEcCtD
Everolimus—Angioedema—Temozolomide—brain cancer	0.000395	0.000967	CcSEcCtD
Everolimus—Decreased appetite—Hydroxyurea—brain cancer	0.000393	0.000961	CcSEcCtD
Everolimus—Urinary tract disorder—Etoposide—brain cancer	0.000392	0.000961	CcSEcCtD
Everolimus—Gastrointestinal disorder—Hydroxyurea—brain cancer	0.00039	0.000954	CcSEcCtD
Everolimus—Malaise—Temozolomide—brain cancer	0.00039	0.000954	CcSEcCtD
Everolimus—Urethral disorder—Etoposide—brain cancer	0.00039	0.000953	CcSEcCtD
Everolimus—Fatigue—Hydroxyurea—brain cancer	0.000389	0.000953	CcSEcCtD
Everolimus—Convulsion—Carmustine—brain cancer	0.000388	0.000949	CcSEcCtD
Everolimus—MTOR—Senescence and Autophagy in Cancer—CDKN2A—brain cancer	0.000387	0.0018	CbGpPWpGaD
Everolimus—Leukopenia—Temozolomide—brain cancer	0.000387	0.000947	CcSEcCtD
Everolimus—Hypertension—Carmustine—brain cancer	0.000386	0.000945	CcSEcCtD
Everolimus—Pain—Hydroxyurea—brain cancer	0.000386	0.000945	CcSEcCtD
Everolimus—Constipation—Hydroxyurea—brain cancer	0.000386	0.000945	CcSEcCtD
Everolimus—Dizziness—Procarbazine—brain cancer	0.000386	0.000945	CcSEcCtD
Everolimus—MTOR—Insulin Signaling—IRS2—brain cancer	0.000386	0.00179	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—SPP1—brain cancer	0.000385	0.00179	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—IRS2—brain cancer	0.000384	0.00178	CbGpPWpGaD
Everolimus—MTOR—PI3K/AKT activation—ERBB2—brain cancer	0.000382	0.00178	CbGpPWpGaD
Everolimus—Palpitations—Temozolomide—brain cancer	0.000382	0.000935	CcSEcCtD
Everolimus—MTOR—Signaling by FGFR—IRS2—brain cancer	0.000382	0.00177	CbGpPWpGaD
Everolimus—Chest pain—Carmustine—brain cancer	0.000381	0.000932	CcSEcCtD
Everolimus—Myalgia—Carmustine—brain cancer	0.000381	0.000932	CcSEcCtD
Everolimus—MTOR—TSH signaling pathway—MYC—brain cancer	0.000381	0.00177	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—IRS2—brain cancer	0.00038	0.00177	CbGpPWpGaD
Everolimus—Anxiety—Carmustine—brain cancer	0.00038	0.000929	CcSEcCtD
Everolimus—MTOR—GAB1 signalosome—ERBB2—brain cancer	0.000379	0.00176	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—CDK4—brain cancer	0.000379	0.00176	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—IRS2—brain cancer	0.000378	0.00176	CbGpPWpGaD
Everolimus—Cough—Temozolomide—brain cancer	0.000377	0.000923	CcSEcCtD
Everolimus—MTOR—B Cell Activation—PDGFRA—brain cancer	0.000375	0.00174	CbGpPWpGaD
Everolimus—Convulsion—Temozolomide—brain cancer	0.000375	0.000917	CcSEcCtD
Everolimus—Hypertension—Temozolomide—brain cancer	0.000373	0.000914	CcSEcCtD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—IRS2—brain cancer	0.000373	0.00173	CbGpPWpGaD
Everolimus—Feeling abnormal—Hydroxyurea—brain cancer	0.000372	0.000911	CcSEcCtD
Everolimus—MTOR—Regulation of Telomerase—MYC—brain cancer	0.000372	0.00173	CbGpPWpGaD
Everolimus—Eye disorder—Etoposide—brain cancer	0.000371	0.000909	CcSEcCtD
Everolimus—Vomiting—Procarbazine—brain cancer	0.000371	0.000908	CcSEcCtD
Everolimus—MTOR—BDNF signaling pathway—APC—brain cancer	0.000371	0.00172	CbGpPWpGaD
Everolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—ERBB2—brain cancer	0.00037	0.00172	CbGpPWpGaD
Everolimus—MTOR—Leptin signaling pathway—STAT3—brain cancer	0.00037	0.00172	CbGpPWpGaD
Everolimus—Flushing—Etoposide—brain cancer	0.000369	0.000903	CcSEcCtD
Everolimus—Cardiac disorder—Etoposide—brain cancer	0.000369	0.000903	CcSEcCtD
Everolimus—Arthralgia—Temozolomide—brain cancer	0.000368	0.000901	CcSEcCtD
Everolimus—Myalgia—Temozolomide—brain cancer	0.000368	0.000901	CcSEcCtD
Everolimus—Rash—Procarbazine—brain cancer	0.000368	0.000901	CcSEcCtD
Everolimus—Dermatitis—Procarbazine—brain cancer	0.000368	0.0009	CcSEcCtD
Everolimus—MTOR—ErbB Signaling Pathway—TP53—brain cancer	0.000367	0.0017	CbGpPWpGaD
Everolimus—Anxiety—Temozolomide—brain cancer	0.000367	0.000898	CcSEcCtD
Everolimus—MTOR—Disease—DTX2—brain cancer	0.000367	0.0017	CbGpPWpGaD
Everolimus—Headache—Procarbazine—brain cancer	0.000366	0.000895	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—brain cancer	0.000366	0.000895	CcSEcCtD
Everolimus—Oedema—Carmustine—brain cancer	0.000365	0.000894	CcSEcCtD
Everolimus—Discomfort—Temozolomide—brain cancer	0.000364	0.00089	CcSEcCtD
Everolimus—MTOR—Regulation of Telomerase—EGFR—brain cancer	0.000363	0.00169	CbGpPWpGaD
Everolimus—Infection—Carmustine—brain cancer	0.000363	0.000888	CcSEcCtD
Everolimus—Angiopathy—Etoposide—brain cancer	0.000361	0.000882	CcSEcCtD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—CCND1—brain cancer	0.000361	0.00168	CbGpPWpGaD
Everolimus—Dry mouth—Temozolomide—brain cancer	0.00036	0.000881	CcSEcCtD
Everolimus—Immune system disorder—Etoposide—brain cancer	0.000359	0.000879	CcSEcCtD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—PDGFRA—brain cancer	0.000359	0.00167	CbGpPWpGaD
Everolimus—Mediastinal disorder—Etoposide—brain cancer	0.000358	0.000877	CcSEcCtD
Everolimus—Thrombocytopenia—Carmustine—brain cancer	0.000357	0.000875	CcSEcCtD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—CTNNB1—brain cancer	0.000357	0.00166	CbGpPWpGaD
Everolimus—Body temperature increased—Hydroxyurea—brain cancer	0.000357	0.000874	CcSEcCtD
Everolimus—Chills—Etoposide—brain cancer	0.000357	0.000873	CcSEcCtD
Everolimus—Tachycardia—Carmustine—brain cancer	0.000356	0.000872	CcSEcCtD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—IRS2—brain cancer	0.000356	0.00165	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—IRS2—brain cancer	0.000356	0.00165	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—IRS2—brain cancer	0.000356	0.00165	CbGpPWpGaD
Everolimus—Oedema—Temozolomide—brain cancer	0.000353	0.000864	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR—IRS2—brain cancer	0.000353	0.00164	CbGpPWpGaD
Everolimus—Alopecia—Etoposide—brain cancer	0.000351	0.00086	CcSEcCtD
Everolimus—Infection—Temozolomide—brain cancer	0.000351	0.000858	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR in Cancer—IRS2—brain cancer	0.000349	0.00162	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—TP53—brain cancer	0.000349	0.00162	CbGpPWpGaD
Everolimus—Anorexia—Carmustine—brain cancer	0.000348	0.000852	CcSEcCtD
Everolimus—MTOR—Signaling by PDGF—IRS2—brain cancer	0.000348	0.00162	CbGpPWpGaD
Everolimus—Nausea—Procarbazine—brain cancer	0.000347	0.000848	CcSEcCtD
Everolimus—Nervous system disorder—Temozolomide—brain cancer	0.000346	0.000847	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—PTCH2—brain cancer	0.000346	0.00161	CbGpPWpGaD
Everolimus—Thrombocytopenia—Temozolomide—brain cancer	0.000345	0.000846	CcSEcCtD
Everolimus—Skin disorder—Temozolomide—brain cancer	0.000343	0.000839	CcSEcCtD
Everolimus—Hypotension—Carmustine—brain cancer	0.000341	0.000835	CcSEcCtD
Everolimus—Hyperhidrosis—Temozolomide—brain cancer	0.000341	0.000835	CcSEcCtD
Everolimus—MTOR—Insulin Signaling—PIK3CG—brain cancer	0.000341	0.00158	CbGpPWpGaD
Everolimus—Dysgeusia—Etoposide—brain cancer	0.000339	0.000829	CcSEcCtD
Everolimus—MTOR—CXCR4-mediated signaling events—STAT3—brain cancer	0.000338	0.00157	CbGpPWpGaD
Everolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—STAT3—brain cancer	0.000338	0.00157	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—VAV1—brain cancer	0.000337	0.00157	CbGpPWpGaD
Everolimus—Anorexia—Temozolomide—brain cancer	0.000336	0.000823	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—HES5—brain cancer	0.000335	0.00156	CbGpPWpGaD
Everolimus—Back pain—Etoposide—brain cancer	0.000335	0.000819	CcSEcCtD
Everolimus—Hypersensitivity—Hydroxyurea—brain cancer	0.000333	0.000814	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Carmustine—brain cancer	0.000333	0.000814	CcSEcCtD
Everolimus—Muscle spasms—Etoposide—brain cancer	0.000333	0.000814	CcSEcCtD
Everolimus—Insomnia—Carmustine—brain cancer	0.00033	0.000808	CcSEcCtD
Everolimus—MTOR—B Cell Activation—IRS2—brain cancer	0.000329	0.00153	CbGpPWpGaD
Everolimus—Paraesthesia—Carmustine—brain cancer	0.000328	0.000802	CcSEcCtD
Everolimus—Dyspnoea—Carmustine—brain cancer	0.000326	0.000797	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—STRADA—brain cancer	0.000325	0.00151	CbGpPWpGaD
Everolimus—Somnolence—Carmustine—brain cancer	0.000325	0.000794	CcSEcCtD
Everolimus—Asthenia—Hydroxyurea—brain cancer	0.000324	0.000793	CcSEcCtD
Everolimus—FKBP1A—Disease—IDH1—brain cancer	0.000322	0.0015	CbGpPWpGaD
Everolimus—CYP3A4—Biological oxidations—CYP2C9—brain cancer	0.000322	0.00149	CbGpPWpGaD
Everolimus—Musculoskeletal discomfort—Temozolomide—brain cancer	0.000321	0.000787	CcSEcCtD
Everolimus—Ill-defined disorder—Etoposide—brain cancer	0.000321	0.000786	CcSEcCtD
Everolimus—MTOR—Cellular responses to stress—SIRT1—brain cancer	0.000321	0.00149	CbGpPWpGaD
Everolimus—Anaemia—Etoposide—brain cancer	0.00032	0.000783	CcSEcCtD
Everolimus—MTOR—VEGFA-VEGFR2 Pathway—CTNNB1—brain cancer	0.000319	0.00148	CbGpPWpGaD
Everolimus—Insomnia—Temozolomide—brain cancer	0.000319	0.000781	CcSEcCtD
Everolimus—Decreased appetite—Carmustine—brain cancer	0.000317	0.000777	CcSEcCtD
Everolimus—CYP3A4—Metapathway biotransformation—CYP2C9—brain cancer	0.000317	0.00147	CbGpPWpGaD
Everolimus—Paraesthesia—Temozolomide—brain cancer	0.000317	0.000775	CcSEcCtD
Everolimus—MTOR—Cellular responses to stress—CCNE1—brain cancer	0.000317	0.00147	CbGpPWpGaD
Everolimus—MTOR—Oncostatin M Signaling Pathway—TP53—brain cancer	0.000316	0.00147	CbGpPWpGaD
Everolimus—Gastrointestinal disorder—Carmustine—brain cancer	0.000315	0.000772	CcSEcCtD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—IRS2—brain cancer	0.000315	0.00146	CbGpPWpGaD
Everolimus—Dyspnoea—Temozolomide—brain cancer	0.000315	0.00077	CcSEcCtD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—VEGFA—brain cancer	0.000314	0.00146	CbGpPWpGaD
Everolimus—Somnolence—Temozolomide—brain cancer	0.000314	0.000768	CcSEcCtD
Everolimus—Constipation—Carmustine—brain cancer	0.000312	0.000764	CcSEcCtD
Everolimus—Pain—Carmustine—brain cancer	0.000312	0.000764	CcSEcCtD
Everolimus—Malaise—Etoposide—brain cancer	0.000312	0.000764	CcSEcCtD
Everolimus—Dyspepsia—Temozolomide—brain cancer	0.000311	0.00076	CcSEcCtD
Everolimus—Leukopenia—Etoposide—brain cancer	0.00031	0.000758	CcSEcCtD
Everolimus—Diarrhoea—Hydroxyurea—brain cancer	0.000309	0.000756	CcSEcCtD
Everolimus—MTOR—Cellular responses to stress—SOD2—brain cancer	0.000308	0.00143	CbGpPWpGaD
Everolimus—Decreased appetite—Temozolomide—brain cancer	0.000307	0.000751	CcSEcCtD
Everolimus—FKBP1A—Disease—HEY1—brain cancer	0.000305	0.00142	CbGpPWpGaD
Everolimus—Gastrointestinal disorder—Temozolomide—brain cancer	0.000305	0.000746	CcSEcCtD
Everolimus—Fatigue—Temozolomide—brain cancer	0.000304	0.000745	CcSEcCtD
Everolimus—Loss of consciousness—Etoposide—brain cancer	0.000304	0.000744	CcSEcCtD
Everolimus—Cough—Etoposide—brain cancer	0.000302	0.000739	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—OR4C12—brain cancer	0.000302	0.0014	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—OR14C36—brain cancer	0.000302	0.0014	CbGpPWpGaD
Everolimus—Pain—Temozolomide—brain cancer	0.000302	0.000739	CcSEcCtD
Everolimus—Constipation—Temozolomide—brain cancer	0.000302	0.000739	CcSEcCtD
Everolimus—MTOR—AMPK Signaling—TP53—brain cancer	0.000302	0.0014	CbGpPWpGaD
Everolimus—MTOR—Signaling by VEGF—CTNNB1—brain cancer	0.000301	0.0014	CbGpPWpGaD
Everolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—EGFR—brain cancer	0.000301	0.0014	CbGpPWpGaD
Everolimus—Feeling abnormal—Carmustine—brain cancer	0.000301	0.000736	CcSEcCtD
Everolimus—Convulsion—Etoposide—brain cancer	0.0003	0.000734	CcSEcCtD
Everolimus—FKBP1A—Disease—DLL1—brain cancer	0.000299	0.00139	CbGpPWpGaD
Everolimus—Hypertension—Etoposide—brain cancer	0.000299	0.000731	CcSEcCtD
Everolimus—Dizziness—Hydroxyurea—brain cancer	0.000299	0.000731	CcSEcCtD
Everolimus—Gastrointestinal pain—Carmustine—brain cancer	0.000299	0.000731	CcSEcCtD
Everolimus—Chest pain—Etoposide—brain cancer	0.000295	0.000721	CcSEcCtD
Everolimus—MTOR—Signaling by SCF-KIT—ERBB2—brain cancer	0.000293	0.00136	CbGpPWpGaD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Etoposide—brain cancer	0.000293	0.000716	CcSEcCtD
Everolimus—Discomfort—Etoposide—brain cancer	0.000291	0.000712	CcSEcCtD
Everolimus—Feeling abnormal—Temozolomide—brain cancer	0.000291	0.000712	CcSEcCtD
Everolimus—MTOR—BDNF signaling pathway—RELA—brain cancer	0.00029	0.00135	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—MYC—brain cancer	0.000289	0.00134	CbGpPWpGaD
Everolimus—Abdominal pain—Carmustine—brain cancer	0.000289	0.000706	CcSEcCtD
Everolimus—Body temperature increased—Carmustine—brain cancer	0.000289	0.000706	CcSEcCtD
Everolimus—Gastrointestinal pain—Temozolomide—brain cancer	0.000289	0.000706	CcSEcCtD
Everolimus—Vomiting—Hydroxyurea—brain cancer	0.000287	0.000703	CcSEcCtD
Everolimus—Rash—Hydroxyurea—brain cancer	0.000285	0.000697	CcSEcCtD
Everolimus—Dermatitis—Hydroxyurea—brain cancer	0.000285	0.000696	CcSEcCtD
Everolimus—Headache—Hydroxyurea—brain cancer	0.000283	0.000693	CcSEcCtD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—EGFR—brain cancer	0.000283	0.00131	CbGpPWpGaD
Everolimus—MTOR—ErbB1 downstream signaling—STAT3—brain cancer	0.000283	0.00131	CbGpPWpGaD
Everolimus—MTOR—VEGFA-VEGFR2 Pathway—VEGFA—brain cancer	0.000281	0.00131	CbGpPWpGaD
Everolimus—Infection—Etoposide—brain cancer	0.000281	0.000687	CcSEcCtD
Everolimus—MTOR—Downstream signaling of activated FGFR—ERBB2—brain cancer	0.00028	0.0013	CbGpPWpGaD
Everolimus—Abdominal pain—Temozolomide—brain cancer	0.000279	0.000683	CcSEcCtD
Everolimus—Body temperature increased—Temozolomide—brain cancer	0.000279	0.000683	CcSEcCtD
Everolimus—Thrombocytopenia—Etoposide—brain cancer	0.000276	0.000677	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—PDGFRA—brain cancer	0.000276	0.00128	CbGpPWpGaD
Everolimus—Tachycardia—Etoposide—brain cancer	0.000276	0.000674	CcSEcCtD
Everolimus—MTOR—Signaling by ERBB4—ERBB2—brain cancer	0.000276	0.00128	CbGpPWpGaD
Everolimus—Skin disorder—Etoposide—brain cancer	0.000274	0.000671	CcSEcCtD
Everolimus—Hyperhidrosis—Etoposide—brain cancer	0.000273	0.000668	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—ABR—brain cancer	0.000271	0.00126	CbGpPWpGaD
Everolimus—MTOR—PI-3K cascade—EGFR—brain cancer	0.000271	0.00126	CbGpPWpGaD
Everolimus—Anorexia—Etoposide—brain cancer	0.000269	0.000659	CcSEcCtD
Everolimus—Hypersensitivity—Carmustine—brain cancer	0.000269	0.000658	CcSEcCtD
Everolimus—MTOR—Disease—HES5—brain cancer	0.000269	0.00125	CbGpPWpGaD
Everolimus—Nausea—Hydroxyurea—brain cancer	0.000268	0.000657	CcSEcCtD
Everolimus—MTOR—Signaling by VEGF—VEGFA—brain cancer	0.000265	0.00123	CbGpPWpGaD
Everolimus—MTOR—PI3K/AKT activation—EGFR—brain cancer	0.000265	0.00123	CbGpPWpGaD
Everolimus—Hypotension—Etoposide—brain cancer	0.000264	0.000646	CcSEcCtD
Everolimus—MTOR—Downstream signal transduction—ERBB2—brain cancer	0.000263	0.00122	CbGpPWpGaD
Everolimus—MTOR—GAB1 signalosome—EGFR—brain cancer	0.000263	0.00122	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—GLI2—brain cancer	0.000262	0.00122	CbGpPWpGaD
Everolimus—Asthenia—Carmustine—brain cancer	0.000262	0.000641	CcSEcCtD
Everolimus—MTOR—Signaling by FGFR—ERBB2—brain cancer	0.000262	0.00122	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—ERBB2—brain cancer	0.000262	0.00122	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—ERBB2—brain cancer	0.000261	0.00121	CbGpPWpGaD
Everolimus—Hypersensitivity—Temozolomide—brain cancer	0.00026	0.000636	CcSEcCtD
Everolimus—MTOR—DAP12 signaling—ERBB2—brain cancer	0.000259	0.0012	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—RELA—brain cancer	0.000257	0.00119	CbGpPWpGaD
Everolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—EGFR—brain cancer	0.000257	0.00119	CbGpPWpGaD
Everolimus—MTOR—ErbB1 downstream signaling—EGFR—brain cancer	0.000257	0.00119	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—DTX2—brain cancer	0.000257	0.00119	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—ERBB2—brain cancer	0.000256	0.00119	CbGpPWpGaD
Everolimus—FKBP1A—Disease—SHH—brain cancer	0.000254	0.00118	CbGpPWpGaD
Everolimus—FKBP1A—Disease—ENO2—brain cancer	0.000254	0.00118	CbGpPWpGaD
Everolimus—Paraesthesia—Etoposide—brain cancer	0.000254	0.000621	CcSEcCtD
Everolimus—Asthenia—Temozolomide—brain cancer	0.000253	0.00062	CcSEcCtD
Everolimus—Dyspnoea—Etoposide—brain cancer	0.000252	0.000616	CcSEcCtD
Everolimus—MTOR—BDNF signaling pathway—CTNNB1—brain cancer	0.000252	0.00117	CbGpPWpGaD
Everolimus—Somnolence—Etoposide—brain cancer	0.000251	0.000614	CcSEcCtD
Everolimus—Diarrhoea—Carmustine—brain cancer	0.00025	0.000611	CcSEcCtD
Everolimus—Pruritus—Temozolomide—brain cancer	0.00025	0.000611	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—GLI1—brain cancer	0.000246	0.00114	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—RELA—brain cancer	0.000245	0.00114	CbGpPWpGaD
Everolimus—Decreased appetite—Etoposide—brain cancer	0.000245	0.000601	CcSEcCtD
Everolimus—MTOR—Integrated Breast Cancer Pathway—CCND1—brain cancer	0.000245	0.00114	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—ERBB2—brain cancer	0.000244	0.00113	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—ERBB2—brain cancer	0.000244	0.00113	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—ERBB2—brain cancer	0.000244	0.00113	CbGpPWpGaD
Everolimus—Gastrointestinal disorder—Etoposide—brain cancer	0.000244	0.000597	CcSEcCtD
Everolimus—Fatigue—Etoposide—brain cancer	0.000243	0.000596	CcSEcCtD
Everolimus—MTOR—Cellular responses to stress—CDK4—brain cancer	0.000242	0.00113	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—CTNNB1—brain cancer	0.000242	0.00113	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—IRS2—brain cancer	0.000242	0.00113	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—SKP2—brain cancer	0.000242	0.00113	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—ERBB2—brain cancer	0.000242	0.00112	CbGpPWpGaD
Everolimus—Dizziness—Carmustine—brain cancer	0.000241	0.000591	CcSEcCtD
Everolimus—Constipation—Etoposide—brain cancer	0.000241	0.000591	CcSEcCtD
Everolimus—Pain—Etoposide—brain cancer	0.000241	0.000591	CcSEcCtD
Everolimus—Diarrhoea—Temozolomide—brain cancer	0.000241	0.000591	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR in Cancer—ERBB2—brain cancer	0.00024	0.00111	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—ERBB2—brain cancer	0.000239	0.00111	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TP53—brain cancer	0.000238	0.0011	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—SUFU—brain cancer	0.000234	0.00109	CbGpPWpGaD
Everolimus—Dizziness—Temozolomide—brain cancer	0.000233	0.000571	CcSEcCtD
Everolimus—Feeling abnormal—Etoposide—brain cancer	0.000233	0.000569	CcSEcCtD
Everolimus—Vomiting—Carmustine—brain cancer	0.000232	0.000568	CcSEcCtD
Everolimus—Gastrointestinal pain—Etoposide—brain cancer	0.000231	0.000565	CcSEcCtD
Everolimus—Rash—Carmustine—brain cancer	0.00023	0.000563	CcSEcCtD
Everolimus—Dermatitis—Carmustine—brain cancer	0.00023	0.000563	CcSEcCtD
Everolimus—Headache—Carmustine—brain cancer	0.000229	0.00056	CcSEcCtD
Everolimus—MTOR—B Cell Activation—RELA—brain cancer	0.000227	0.00106	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—ERBB2—brain cancer	0.000226	0.00105	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—GFAP—brain cancer	0.000225	0.00105	CbGpPWpGaD
Everolimus—Vomiting—Temozolomide—brain cancer	0.000224	0.000549	CcSEcCtD
Everolimus—Body temperature increased—Etoposide—brain cancer	0.000223	0.000546	CcSEcCtD
Everolimus—Abdominal pain—Etoposide—brain cancer	0.000223	0.000546	CcSEcCtD
Everolimus—MTOR—Signaling by SCF-KIT—STAT3—brain cancer	0.000223	0.00104	CbGpPWpGaD
Everolimus—Rash—Temozolomide—brain cancer	0.000222	0.000545	CcSEcCtD
Everolimus—Dermatitis—Temozolomide—brain cancer	0.000222	0.000544	CcSEcCtD
Everolimus—Headache—Temozolomide—brain cancer	0.000221	0.000541	CcSEcCtD
Everolimus—MTOR—BDNF signaling pathway—STAT3—brain cancer	0.000219	0.00102	CbGpPWpGaD
Everolimus—Nausea—Carmustine—brain cancer	0.000217	0.000531	CcSEcCtD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—ERBB2—brain cancer	0.000216	0.001	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—TP53—brain cancer	0.000216	0.001	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—HEY1—brain cancer	0.000214	0.000993	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—VEGFA—brain cancer	0.000213	0.000991	CbGpPWpGaD
Everolimus—Nausea—Temozolomide—brain cancer	0.00021	0.000513	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—DLL1—brain cancer	0.00021	0.000973	CbGpPWpGaD
Everolimus—Hypersensitivity—Etoposide—brain cancer	0.000208	0.000509	CcSEcCtD
Everolimus—MTOR—Signaling by SCF-KIT—EGFR—brain cancer	0.000203	0.000942	CbGpPWpGaD
Everolimus—Asthenia—Etoposide—brain cancer	0.000203	0.000496	CcSEcCtD
Everolimus—MTOR—Downstream signal transduction—STAT3—brain cancer	0.000201	0.000932	CbGpPWpGaD
Everolimus—Pruritus—Etoposide—brain cancer	0.0002	0.000489	CcSEcCtD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—STAT3—brain cancer	0.0002	0.000928	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—MYC—brain cancer	0.000196	0.000912	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PTCH2—brain cancer	0.000195	0.000904	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—EGFR—brain cancer	0.000194	0.000902	CbGpPWpGaD
Everolimus—Diarrhoea—Etoposide—brain cancer	0.000193	0.000473	CcSEcCtD
Everolimus—MTOR—Innate Immune System—VAV1—brain cancer	0.000192	0.000893	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—EGFR—brain cancer	0.000192	0.000892	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—EGFR—brain cancer	0.000191	0.000887	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—HES5—brain cancer	0.000188	0.000875	CbGpPWpGaD
Everolimus—Dizziness—Etoposide—brain cancer	0.000187	0.000457	CcSEcCtD
Everolimus—MTOR—Signaling by FGFR in disease—STAT3—brain cancer	0.000186	0.000864	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—CDKN2A—brain cancer	0.000185	0.000861	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—VAV1—brain cancer	0.000185	0.000858	CbGpPWpGaD
Everolimus—FKBP1A—Disease—VAV1—brain cancer	0.000184	0.000854	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—STRADA—brain cancer	0.000183	0.00085	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—EGFR—brain cancer	0.000182	0.000847	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—STAT3—brain cancer	0.000182	0.000845	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—EGFR—brain cancer	0.000181	0.000843	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—EGFR—brain cancer	0.000181	0.000843	CbGpPWpGaD
Everolimus—MTOR—Disease—IDH1—brain cancer	0.000181	0.000841	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—EGFR—brain cancer	0.000181	0.000839	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—EGFR—brain cancer	0.00018	0.000835	CbGpPWpGaD
Everolimus—Vomiting—Etoposide—brain cancer	0.00018	0.000439	CcSEcCtD
Everolimus—MTOR—Cellular responses to stress—RELA—brain cancer	0.000178	0.000828	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—SHH—brain cancer	0.000178	0.000828	CbGpPWpGaD
Everolimus—Rash—Etoposide—brain cancer	0.000178	0.000436	CcSEcCtD
Everolimus—Dermatitis—Etoposide—brain cancer	0.000178	0.000435	CcSEcCtD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—EGFR—brain cancer	0.000177	0.000823	CbGpPWpGaD
Everolimus—Headache—Etoposide—brain cancer	0.000177	0.000433	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—TRPC6—brain cancer	0.000172	0.000798	CbGpPWpGaD
Everolimus—MTOR—Disease—HEY1—brain cancer	0.000172	0.000797	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—EGFR—brain cancer	0.000169	0.000786	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—EGFR—brain cancer	0.000169	0.000786	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—EGFR—brain cancer	0.000169	0.000786	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PTCH1—brain cancer	0.000169	0.000785	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—SMO—brain cancer	0.000169	0.000785	CbGpPWpGaD
Everolimus—MTOR—Disease—DLL1—brain cancer	0.000168	0.000782	CbGpPWpGaD
Everolimus—Nausea—Etoposide—brain cancer	0.000168	0.00041	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR—EGFR—brain cancer	0.000168	0.000778	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—RELA—brain cancer	0.000167	0.000777	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—ERBB2—brain cancer	0.000166	0.000772	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—EGFR—brain cancer	0.000166	0.000772	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—EGFR—brain cancer	0.000165	0.000768	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—STAT3—brain cancer	0.000165	0.000765	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—TP53—brain cancer	0.000161	0.000749	CbGpPWpGaD
Everolimus—FKBP1A—Disease—HES1—brain cancer	0.000158	0.000734	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—PDGFRA—brain cancer	0.000157	0.000731	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—EGFR—brain cancer	0.000156	0.000727	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ABR—brain cancer	0.000153	0.000709	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—PDGFRA—brain cancer	0.000151	0.000702	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PDGFRA—brain cancer	0.000151	0.000699	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—EGFR—brain cancer	0.00015	0.000696	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—GLI2—brain cancer	0.000147	0.000685	CbGpPWpGaD
Everolimus—MTOR—Immune System—SKP2—brain cancer	0.000147	0.000683	CbGpPWpGaD
Everolimus—MTOR—Disease—ENO2—brain cancer	0.000143	0.000665	CbGpPWpGaD
Everolimus—MTOR—Disease—SHH—brain cancer	0.000143	0.000665	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—GLI1—brain cancer	0.000139	0.000644	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—IRS2—brain cancer	0.000138	0.000642	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—VEGFA—brain cancer	0.000136	0.000634	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—STAT3—brain cancer	0.000135	0.000628	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—NOTCH2—brain cancer	0.000135	0.000627	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—IRS2—brain cancer	0.000133	0.000617	CbGpPWpGaD
Everolimus—FKBP1A—Disease—IRS2—brain cancer	0.000132	0.000614	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SUFU—brain cancer	0.000131	0.00061	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—VAV1—brain cancer	0.000129	0.000598	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—GFAP—brain cancer	0.000127	0.000589	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—STAT3—brain cancer	0.000127	0.000589	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—HEY1—brain cancer	0.00012	0.000558	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—DLL1—brain cancer	0.000118	0.000547	CbGpPWpGaD
Everolimus—FKBP1A—Disease—APC—brain cancer	0.000117	0.000542	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—EGFR—brain cancer	0.000115	0.000535	CbGpPWpGaD
Everolimus—MTOR—Immune System—VAV1—brain cancer	0.000112	0.00052	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—HES1—brain cancer	0.000111	0.000514	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PDGFRA—brain cancer	0.000105	0.00049	CbGpPWpGaD
Everolimus—MTOR—Disease—VAV1—brain cancer	0.000103	0.00048	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—TP53—brain cancer	0.000103	0.000479	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—SPP1—brain cancer	0.000102	0.000475	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SHH—brain cancer	0.0001	0.000466	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TRPC6—brain cancer	9.66e-05	0.000449	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—RELA—brain cancer	9.54e-05	0.000443	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PTCH1—brain cancer	9.5e-05	0.000441	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SMO—brain cancer	9.5e-05	0.000441	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—ERBB2—brain cancer	9.48e-05	0.00044	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IRS2—brain cancer	9.25e-05	0.00043	CbGpPWpGaD
Everolimus—MTOR—Immune System—PDGFRA—brain cancer	9.17e-05	0.000426	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—RELA—brain cancer	9.16e-05	0.000425	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—ERBB2—brain cancer	9.1e-05	0.000423	CbGpPWpGaD
Everolimus—FKBP1A—Disease—ERBB2—brain cancer	9.06e-05	0.000421	CbGpPWpGaD
Everolimus—MTOR—Disease—HES1—brain cancer	8.89e-05	0.000413	CbGpPWpGaD
Everolimus—MTOR—Disease—PDGFRA—brain cancer	8.47e-05	0.000393	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—CTNNB1—brain cancer	8.29e-05	0.000385	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—APC—brain cancer	8.17e-05	0.00038	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PIK3CG—brain cancer	8.17e-05	0.00038	CbGpPWpGaD
Everolimus—MTOR—Immune System—IRS2—brain cancer	8.05e-05	0.000374	CbGpPWpGaD
Everolimus—FKBP1A—Disease—CTNNB1—brain cancer	7.93e-05	0.000368	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NOTCH2—brain cancer	7.59e-05	0.000353	CbGpPWpGaD
Everolimus—MTOR—Disease—IRS2—brain cancer	7.43e-05	0.000345	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—VAV1—brain cancer	7.24e-05	0.000336	CbGpPWpGaD
Everolimus—FKBP1A—Disease—STAT3—brain cancer	6.91e-05	0.000321	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—EGFR—brain cancer	6.57e-05	0.000305	CbGpPWpGaD
Everolimus—MTOR—Disease—APC—brain cancer	6.56e-05	0.000305	CbGpPWpGaD
Everolimus—FKBP1A—Disease—MYC—brain cancer	6.42e-05	0.000298	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—RELA—brain cancer	6.39e-05	0.000297	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—ERBB2—brain cancer	6.35e-05	0.000295	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—EGFR—brain cancer	6.31e-05	0.000293	CbGpPWpGaD
Everolimus—FKBP1A—Disease—EGFR—brain cancer	6.28e-05	0.000292	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—HES1—brain cancer	6.23e-05	0.000289	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PDGFRA—brain cancer	5.93e-05	0.000275	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SPP1—brain cancer	5.75e-05	0.000267	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IL2—brain cancer	5.75e-05	0.000267	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CCND1—brain cancer	5.61e-05	0.00026	CbGpPWpGaD
Everolimus—MTOR—Immune System—RELA—brain cancer	5.56e-05	0.000258	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CTNNB1—brain cancer	5.55e-05	0.000258	CbGpPWpGaD
Everolimus—MTOR—Immune System—ERBB2—brain cancer	5.52e-05	0.000256	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CYP2C9—brain cancer	5.5e-05	0.000255	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IRS2—brain cancer	5.2e-05	0.000242	CbGpPWpGaD
Everolimus—MTOR—Disease—ERBB2—brain cancer	5.1e-05	0.000237	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL2—brain cancer	5e-05	0.000232	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—VEGFA—brain cancer	4.89e-05	0.000227	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—STAT3—brain cancer	4.84e-05	0.000225	CbGpPWpGaD
Everolimus—MTOR—Immune System—CTNNB1—brain cancer	4.83e-05	0.000224	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—BSG—brain cancer	4.68e-05	0.000217	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PIK3CG—brain cancer	4.6e-05	0.000214	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—APC—brain cancer	4.6e-05	0.000214	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MYC—brain cancer	4.5e-05	0.000209	CbGpPWpGaD
Everolimus—MTOR—Disease—CTNNB1—brain cancer	4.46e-05	0.000207	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—EGFR—brain cancer	4.4e-05	0.000204	CbGpPWpGaD
Everolimus—MTOR—Immune System—STAT3—brain cancer	4.21e-05	0.000196	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—IDH1—brain cancer	4.02e-05	0.000187	CbGpPWpGaD
Everolimus—MTOR—Disease—STAT3—brain cancer	3.89e-05	0.000181	CbGpPWpGaD
Everolimus—MTOR—Immune System—EGFR—brain cancer	3.83e-05	0.000178	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TP53—brain cancer	3.69e-05	0.000172	CbGpPWpGaD
Everolimus—MTOR—Disease—MYC—brain cancer	3.61e-05	0.000168	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—RELA—brain cancer	3.59e-05	0.000167	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ERBB2—brain cancer	3.57e-05	0.000166	CbGpPWpGaD
Everolimus—MTOR—Disease—EGFR—brain cancer	3.53e-05	0.000164	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IL2—brain cancer	3.23e-05	0.00015	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ENO2—brain cancer	3.18e-05	0.000148	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CCND1—brain cancer	3.15e-05	0.000146	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CTNNB1—brain cancer	3.12e-05	0.000145	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—VEGFA—brain cancer	2.75e-05	0.000128	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—STAT3—brain cancer	2.72e-05	0.000126	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MYC—brain cancer	2.53e-05	0.000118	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—EGFR—brain cancer	2.47e-05	0.000115	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TP53—brain cancer	2.08e-05	9.65e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PIK3CG—brain cancer	1.46e-05	6.77e-05	CbGpPWpGaD
